<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9474">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05037929</url>
  </required_header>
  <id_info>
    <org_study_id>GB43311</org_study_id>
    <nct_id>NCT05037929</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in&#xD;
      combination with standard of care chronic obstructive pulmonary disease (COPD) maintenance&#xD;
      therapy in patients with COPD who are former or current smokers and have a history of&#xD;
      frequent exacerbations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized Rate of Moderate and Severe COPD Exacerbations Over the 52-Week Treatment Period</measure>
    <time_frame>Baseline up to Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to First Moderate or Severe COPD Exacerbation During the 52-Week Treatment Period</measure>
    <time_frame>Baseline up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change from Baseline in Health-Related Quality of Life (HRQoL) at Week 52 as Assessed Through the St. George's Respiratory Questionnaire-COPD (SGRQ-C) Total Score</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of SGRQ-C Responders at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change from Baseline in Post-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (liters) at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change from Baseline in Evaluating Respiratory Symptoms in COPD (E-RS:COPD) Total Score at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Rate of Severe COPD Exacerbations Over the 52-Week Treatment Period</measure>
    <time_frame>Baseline up to Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">930</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Astegolimab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive subcutaneous (SC) astegolimab every 2 weeks (Q2W).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Astegolimab Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive alternating SC astegolimab and placebo Q2W, thus receiving astegolimab every 4 weeks (Q4W).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive SC placebo Q2W.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Astegolimab</intervention_name>
    <description>Participants will receive SC astegolimab Q2W or Q4W.</description>
    <arm_group_label>Astegolimab Q2W</arm_group_label>
    <arm_group_label>Astegolimab Q4W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive SC placebo Q2W.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Documented physician diagnosis of COPD for at least 12 months&#xD;
&#xD;
          -  History of frequent exacerbations, defined as having had two or more moderate or&#xD;
             severe exacerbations occurring within a 12-month period in the 24 months prior to&#xD;
             screening&#xD;
&#xD;
          -  Post-bronchodilator FEV1 &gt;=20 and &lt;80% of predicted normal value at screening&#xD;
&#xD;
          -  Modified Medical Research Council (dyspnea scale) (mMRC) score &gt;=2&#xD;
&#xD;
          -  Current or former smoker with a minimum of 10 pack-year history&#xD;
&#xD;
          -  History of one of the following combinations of optimized, stable, standard-of-care&#xD;
             COPD maintenance therapy for at least 4 weeks prior to screening, with no anticipated&#xD;
             changes in therapy prior to initiation of study drug and throughout the study: Inhaled&#xD;
             corticosteroid (ICS) plus long-acting beta-agonist (LABA); Long-acting muscarinic&#xD;
             antagonist (LAMA) plus LABA; ICS plus LAMA plus LABA&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Current documented diagnosis of asthma according to the Global Initiative for Asthma&#xD;
             guidelines or other accepted guidelines within 5 years prior to screening&#xD;
&#xD;
          -  History of clinically significant pulmonary disease other than COPD&#xD;
&#xD;
          -  History of long-term treatment with oxygen at &gt;4.0 liters/minute&#xD;
&#xD;
          -  Lung volume reduction surgery or procedure within 12 months prior to screening&#xD;
&#xD;
          -  Participation in or planned participation in a new pulmonary rehabilitation program.&#xD;
             Patients who are in the maintenance phase of a rehabilitation program are eligible&#xD;
&#xD;
          -  History of lung transplant&#xD;
&#xD;
          -  Occurrence of moderate or severe COPD exacerbation, COVID-19, upper or lower&#xD;
             respiratory infection, pneumonia, or hospitalization of 24 hours duration within 4&#xD;
             weeks prior to initiation of study drug&#xD;
&#xD;
          -  Treatment with oral, IV, or IM corticosteroids within 4 weeks prior to initiation of&#xD;
             study drug&#xD;
&#xD;
          -  Initiation of a methylxanthine preparation, maintenance macrolide therapy, and/or PDE4&#xD;
             inhibitor within 4 weeks prior to screening&#xD;
&#xD;
          -  Unstable cardiac disease, myocardial infarction, or New York Heart Association Class&#xD;
             III or IV heart failure within 12 months prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GB43311 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>SEC Clinical Research LLC - Andalusia - ClinEdge - PPDS</name>
      <address>
        <city>Andalusia</city>
        <state>Alabama</state>
        <zip>36420-5310</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jasper Summit Research LLC</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <zip>35501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Phoenix Medical Group PC</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381-4872</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Allianz Research Institute Inc</name>
      <address>
        <city>Westminster</city>
        <state>California</state>
        <zip>92683</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Suncoast Research Group LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Institute for Clinical Research, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Revive Research Institute</name>
      <address>
        <city>Lathrup Village</city>
        <state>Michigan</state>
        <zip>48076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oakland Medical Research</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Gastonia</name>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <zip>28054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carolina Research Center</name>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <zip>28150-3803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southeastern Research Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103-4029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carolina Medical Research, LLC</name>
      <address>
        <city>Clinton</city>
        <state>South Carolina</state>
        <zip>29325-7556</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Piedmont Research Partners LLC - Clinedge - PPDS</name>
      <address>
        <city>Fort Mill</city>
        <state>South Carolina</state>
        <zip>29707-4526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Rock Hill</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Texas Medical Research Institute, Inc., dba TTS Research - ClinEdge - PPDS</name>
      <address>
        <city>Boerne</city>
        <state>Texas</state>
        <zip>78006-1993</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Horizon Clinical Research Group: Houston Pulmonary Sleep &amp; Allergy Associates -Clinedge - PPDS</name>
      <address>
        <city>Cypress</city>
        <state>Texas</state>
        <zip>77429-4696</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 31, 2021</study_first_submitted>
  <study_first_submitted_qc>August 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

